Case Report: Severe Complement-Mediated Thrombotic Microangiopathy in IgG4-Related Disease Secondary to Anti-Factor H IgG4 Autoantibodies
ObjectiveTo first describe and estimate the potential pathogenic role of Ig4 autoantibodies in complement-mediated thrombotic microangiopathy (TMA) in a patient with IgG4-related disease (IgG4-RD).MethodsThis study is a case report presenting a retrospective review of the patient’s medical chart. Plasma complement C3 and C4 levels, immunoglobulin isotypes and subclasses were determined by nephelometry, the complement pathways’ activity (CH50, AP50, MBL) using WIESLAB® Complement System assays. Human complement factor H levels, anti-complement factor H auto-antibodies were analyzed by ELISA, using HRP-labeled secondary antibodies specific for human IgG, IgG4, and IgA, respectively. Genetic analyses were performed by exome sequencing of 14 gens implicated in complement disorders, as well as multiplex ligation-dependent probe amplification looking specifically for CFH, CFHR1-2-3, and 5.ResultsOur brief report presents the first case of IgG4-RD with complement-mediated TMA originating from both pathogenic CFHR 1 and CFHR 4 genes deletions, and inhibitory anti-complement factor H autoantibodies of the IgG4 subclass. Remission was achieved with plasmaphereses, corticosteroids, and cyclophosphamide. Following remission, the patient was diagnosed with lymphocytic meningitis and SARS-CoV-2 pneumonia with an uneventful recovery.ConclusionIgG4-RD can be associated with pathogenic IgG4 autoantibodies. Genetic predisposition such as CFHR1 and CFHR4 gene deletions enhance the susceptibility to the formation of inhibitory anti-Factor H IgG4 antibodies..
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:11 |
|---|---|
| Enthalten in: |
Frontiers in Immunology - 11(2021) |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Gautier Breville [VerfasserIn] |
|---|
| Links: |
doi.org [kostenfrei] |
|---|
| Themen: |
Antibodies |
|---|
| doi: |
10.3389/fimmu.2020.604759 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
DOAJ015063259 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | DOAJ015063259 | ||
| 003 | DE-627 | ||
| 005 | 20230310072536.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 230226s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.3389/fimmu.2020.604759 |2 doi | |
| 035 | |a (DE-627)DOAJ015063259 | ||
| 035 | |a (DE-599)DOAJb6c4b322fb2a46c0ad0a1791b3c0c5e2 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 050 | 0 | |a RC581-607 | |
| 100 | 0 | |a Gautier Breville |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Case Report: Severe Complement-Mediated Thrombotic Microangiopathy in IgG4-Related Disease Secondary to Anti-Factor H IgG4 Autoantibodies |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a ObjectiveTo first describe and estimate the potential pathogenic role of Ig4 autoantibodies in complement-mediated thrombotic microangiopathy (TMA) in a patient with IgG4-related disease (IgG4-RD).MethodsThis study is a case report presenting a retrospective review of the patient’s medical chart. Plasma complement C3 and C4 levels, immunoglobulin isotypes and subclasses were determined by nephelometry, the complement pathways’ activity (CH50, AP50, MBL) using WIESLAB® Complement System assays. Human complement factor H levels, anti-complement factor H auto-antibodies were analyzed by ELISA, using HRP-labeled secondary antibodies specific for human IgG, IgG4, and IgA, respectively. Genetic analyses were performed by exome sequencing of 14 gens implicated in complement disorders, as well as multiplex ligation-dependent probe amplification looking specifically for CFH, CFHR1-2-3, and 5.ResultsOur brief report presents the first case of IgG4-RD with complement-mediated TMA originating from both pathogenic CFHR 1 and CFHR 4 genes deletions, and inhibitory anti-complement factor H autoantibodies of the IgG4 subclass. Remission was achieved with plasmaphereses, corticosteroids, and cyclophosphamide. Following remission, the patient was diagnosed with lymphocytic meningitis and SARS-CoV-2 pneumonia with an uneventful recovery.ConclusionIgG4-RD can be associated with pathogenic IgG4 autoantibodies. Genetic predisposition such as CFHR1 and CFHR4 gene deletions enhance the susceptibility to the formation of inhibitory anti-Factor H IgG4 antibodies. | ||
| 650 | 4 | |a thrombotic microangiopathy | |
| 650 | 4 | |a atypical hemolytic uremic syndrome | |
| 650 | 4 | |a IgG4-related disease | |
| 650 | 4 | |a antibodies | |
| 650 | 4 | |a complement factor H-related protein | |
| 650 | 4 | |a complement factor H | |
| 653 | 0 | |a Immunologic diseases. Allergy | |
| 700 | 0 | |a Gautier Breville |e verfasserin |4 aut | |
| 700 | 0 | |a Ido Zamberg |e verfasserin |4 aut | |
| 700 | 0 | |a Ido Zamberg |e verfasserin |4 aut | |
| 700 | 0 | |a Salima Sadallah |e verfasserin |4 aut | |
| 700 | 0 | |a Caroline Stephan |e verfasserin |4 aut | |
| 700 | 0 | |a Belen Ponte |e verfasserin |4 aut | |
| 700 | 0 | |a Jörg D. Seebach |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i In |t Frontiers in Immunology |d Frontiers Media S.A., 2011 |g 11(2021) |w (DE-627)DOAJ000031690 |x 16643224 |7 nnns |
| 773 | 1 | 8 | |g volume:11 |g year:2021 |
| 856 | 4 | 0 | |u https://doi.org/10.3389/fimmu.2020.604759 |z kostenfrei |
| 856 | 4 | 0 | |u https://doaj.org/article/b6c4b322fb2a46c0ad0a1791b3c0c5e2 |z kostenfrei |
| 856 | 4 | 0 | |u https://www.frontiersin.org/articles/10.3389/fimmu.2020.604759/full |z kostenfrei |
| 856 | 4 | 2 | |u https://doaj.org/toc/1664-3224 |y Journal toc |z kostenfrei |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_DOAJ | ||
| 951 | |a AR | ||
| 952 | |d 11 |j 2021 | ||